Nikhil Gupte, PhD

CRS:

BJMC

Role:

Regulatory and Data ManagementResearch Staff

Position:

CRS Data Manager and Deputy Director

Nikhil Gupte, PhD, is a Research Associate faculty member at the Johns Hopkins School of Medicine and Deputy Director of the Byramjee Jeejeebhoy Government Medical College (BJGMC)-JHU Clinical Trials Unit (CTU), a collaborative research partnership associated with the world’s largest HIV therapeutic trials networks, the AIDS Clinial Trials Group [ACTG] and the International Maternal Pediatric and Adolescent AIDS Clinical Trial Network (IMPAACT).

Dr. Gupte has more than 10 years of experience in public health research in developing countries and is a recognized leader in biostatistics education in India. Based in Pune, India, Dr. Gupte is the lead statistician for the BJGMC-JHU CTU, which conducts Phase I, II and III clinical trials of therapeutic drug interventions for HIV and co-morbid infections, such as tuberculosis and hepatitis, in adults (including pregnant women) and children. An experienced educator, Dr. Gupte has developed and taught biostatistics courses in India, including a number of University courses and NIH-supported training courses, and he currently leads the Biostatistics training for the BJGMC-JHU Fogarty HIV-TB Training Program.

A recipient of the Hopkins Fogarty fellowship, Dr. Gupte received a Doctor of Philosophy in Biostatistics from the Johns Hopkins Bloomberg School of Public Health.

  • Member, Site Operations Subcommittee
  • NWCS 319, parent study A5175
  • NWCS 408, parent study A5274
  • NWCS 414, parent study A5274

.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P1077BF: Breastfeeding Version of the PROMISE Study...

1077BF is a randomized strategy trial, which is part of the PROMISE studies (1077BF, 1077FF, P1084s, and 1077HS). The Promoting...

Read More

HPTN 078: Enhancing Recruitment, Linkage to Care and...

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

Read More

A5332: Randomized Trial to Prevent Vascular Events in HIV...

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....

Read More

P1060:  Phase II, parallel, randomized, clinical trials...

A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been...

Read More

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More